Inclusion Criteria:

- Histologically documented unresectable stage III NSCLC. Mediastinal (N2) involvement
must be confirmed by biopsy

- Stable disease or clinical response after primary therapy of chemo-radiation
treatment for unresectable stage III disease

- Primary therapy should be a minimum of 2 cycles of Platinum-based first-line
chemotherapy, given concurrent with thoracic radiation. The combined modality should
consist of either:

- induction (2 cycles) chemotherapy followed by concurrent chemo/RT; or

- concurrent chemo/RT followed by 2 cycles of consolidation chemotherapy; or

- concurrent chemo/RT alone

- A minimum radiation dose of ≥6,000cGy should be administered. Patients must have
completed the primary therapy at least 4 weeks and no later than 6 months prior to
study entry

- ECOG performance status of ≤1

- Ability to understand and willingness to sign a written informed consent

Exclusion Criteria:

- Undergone lung cancer specific therapy (including surgery) prior to primary chemo/RT

- Received immunotherapy within 4 weeks prior to study entry

- Received systemic immunosuppressive drugs within 4 weeks prior to study entry

- Received investigational systemic drugs within 4 weeks prior to study entry

- Brain metastases

- Pleural effusion, unless cytologically confirmed to be non-malignant

- Past or current history of neoplasm other than lung carcinoma, except for curatively
treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer
curatively treated and with no evidence of disease for at least 5 years

- Autoimmune disease or immunodeficiency

- Clinically significant hepatic, renal or cardiac dysfunction

- Clinically significant active infection

- Pregnant or lactating, women of childbearing potential, unless using effective
contraception as determined by the investigator